Last edition
News about "Oral Semaglutide "
FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes
Rybelsus (Semaglutide) tablets, available in 7 mg and 14 mg doses, is the only FDA-approved oral GLP-1 therapy, and is now indicated to lower the risk of Major Adverse Cardiovascular Events (MACE)—including CV death, heart attack, or stroke—in adults with type 2 diabetes at high cardiovascular risk.
Oral Semaglutide | 21/10/2025 | By Dineshwori | 143
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members